Daiichi Sankyo (OTCMKTS:DSNKY) Updates FY 2026 Earnings Guidance

Daiichi Sankyo (OTCMKTS:DSNKY) updated its FY 2026 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of 0.870-0.870 for the period, compared to the consensus EPS estimate of 1.040. The company issued revenue guidance of $14.7 billion-$14.7 billion, compared to the consensus revenue estimate of $13.4 billion.

Daiichi Sankyo Trading Down 11.5%

Shares of OTCMKTS:DSNKY opened at $16.14 on Friday. The stock has a 50 day moving average of $16.51 and a 200 day moving average of $17.73. The company has a market cap of $30.07 billion, a PE ratio of 18.77, a price-to-earnings-growth ratio of 2.83 and a beta of -0.17. The company has a current ratio of 2.42, a quick ratio of 1.64 and a debt-to-equity ratio of 0.18. Daiichi Sankyo has a 12-month low of $14.98 and a 12-month high of $27.50.

Daiichi Sankyo (OTCMKTS:DSNKY) last released its earnings results on Friday, July 31st. The company reported $0.24 EPS for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). Daiichi Sankyo had a return on equity of 15.75% and a net margin of 12.32%.The firm had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.32 billion. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. As a group, equities research analysts expect that Daiichi Sankyo will post 0.96 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Jefferies Financial Group downgraded shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a report on Thursday. Zacks Research raised Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a report on Tuesday, May 5th. Two equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold”.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.